Cannabidiol helps reduce Atonic Seizure in people facing Lennox-Gastaut Syndrome that causes muscle tone loss and sudden falls. Lennox-Gastaut Syndrome was responding to the earlier treatments, says a randomized clinical trial of phase 3.
Nearly 1 to 4 per cent of epilepsy cases in children are triggered by Lennox-Gastaut syndrome, which is a life-lasting and extremely critical type of epilepsy that includes a multiple seizure forms as well as cognitive impairment.
Wide range of non-pharmacological treatments and drugs such as nerve stimulation, ketogenic diet and brain surgery are available which are helpful for only 10 per cents of patients as making them seizure free.
Neurologist in Boston, Dr. Elizabeth Thiele from the Massachusetts General Hospital, United States said in a statement that, “There is an urgent need for novel treatment options for patients with Lennox-Gastaut syndrome, and we are pleased that our study has potentially found an additional option to add to patients’ existing treatment to reduce drop seizures.”
The trial lasted up to 14 weeks, which has reduced seizures’ frequency, while the long term safety and efficacy of the cannabidiol’s pharmaceutical formulation and interaction of the drug with another epilepsy drugs that now has to be confirmed.
Thiele added that, “Our results suggest that the use of cannabidiol as an add-on therapy with other anti-epilepsy drugs might significantly reduce the frequency of drop seizures in patients with Lennox-Gastaut syndrome, which is positive news for these patients, who often do not respond to treatment.”